Biologics and Biosimilars in Psoriasis

Psoriasis is a chronic, debilitating, relapsing, inflammatory dermatosis, which affects approximately 2-3% of the population. The burgeoning research on pathogenesis of psoriasis has opened up new directions in management of this common condition. The introduction of biologics has given additional elements to the arsenal of psoriatic disease treatments. TNF-a inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, CD-6 inhibitor proved highly efficient and have a good safety profile in numerous clinical trials. Biosimilar drugs are structurally almost similar to their reference biologic and are also made from living organism. Long-term follow-up and post-marketing surveillance are required to understand, long-term efficacy, adverse events of these powerful potent molecules.

Automated summary

Psoriasis is a chronic inflammatory skin disease that affects around 2-3% of the population. Advancements in understanding its pathogenesis have led to new treatment options, such as biologics. Biologics, including TNF-a inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and CD-6 inhibitors, have shown high efficacy and safety in clinical trials. Long-term follow-up and post-marketing surveillance are necessary to understand the long-term effectiveness and adverse events of these potent drugs.